276 related articles for article (PubMed ID: 33626430)
1. Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis.
Verberk IMW; Koel-Simmelink M; Twaalfhoven H; Vrenken H; Korth C; Killestein J; Teunissen CE; Bridel C
Mult Scler Relat Disord; 2021 May; 50():102840. PubMed ID: 33626430
[TBL] [Abstract][Full Text] [Related]
2. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of CSF neurofilament light and heavy chain protein in MS.
Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
[TBL] [Abstract][Full Text] [Related]
4. The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA.
Koel-Simmelink MJ; Vennegoor A; Killestein J; Blankenstein MA; Norgren N; Korth C; Teunissen CE
J Immunol Methods; 2014 Jan; 402(1-2):43-9. PubMed ID: 24275679
[TBL] [Abstract][Full Text] [Related]
5. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS.
Halbgebauer S; Steinacker P; Verde F; Weishaupt J; Oeckl P; von Arnim C; Dorst J; Feneberg E; Mayer B; Rosenbohm A; Silani V; Ludolph AC; Otto M
J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):68-74. PubMed ID: 34417339
[TBL] [Abstract][Full Text] [Related]
6. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.
Kuhle J; Barro C; Andreasson U; Derfuss T; Lindberg R; Sandelius Å; Liman V; Norgren N; Blennow K; Zetterberg H
Clin Chem Lab Med; 2016 Oct; 54(10):1655-61. PubMed ID: 27071153
[TBL] [Abstract][Full Text] [Related]
7. Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis: From the MS-STAT Randomized Controlled Trial.
Williams TE; Holdsworth KP; Nicholas JM; Eshaghi A; Katsanouli T; Wellington H; Heslegrave A; Zetterberg H; Frost C; Chataway J
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35031587
[TBL] [Abstract][Full Text] [Related]
8. Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
Fox RJ; Raska P; Barro C; Karafa M; Konig V; Bermel RA; Chase M; Coffey CS; Goodman AD; Klawiter EC; Naismith RT; Kuhle J
Mult Scler; 2021 Nov; 27(13):2014-2022. PubMed ID: 33635141
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective.
Arslan B; Ayhan Arslan G; Tuncer A; Karabudak R; Sepici Dinçel A
Bosn J Basic Med Sci; 2022 Sep; 22(5):699-706. PubMed ID: 35490364
[TBL] [Abstract][Full Text] [Related]
10. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation.
Gaetani L; Höglund K; Parnetti L; Pujol-Calderon F; Becker B; Eusebi P; Sarchielli P; Calabresi P; Di Filippo M; Zetterberg H; Blennow K
Alzheimers Res Ther; 2018 Jan; 10(1):8. PubMed ID: 29370869
[TBL] [Abstract][Full Text] [Related]
11. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J;
Ann Neurol; 2017 Jun; 81(6):857-870. PubMed ID: 28512753
[TBL] [Abstract][Full Text] [Related]
12. Microstructural and functional brain abnormalities in multiple sclerosis predicted by osteopontin and neurofilament light.
Orsi G; Cseh T; Hayden Z; Perlaki G; Nagy SA; Giyab O; Olsen DA; Madsen JS; Berki T; Illes Z
Mult Scler Relat Disord; 2021 Jun; 51():102923. PubMed ID: 33813096
[TBL] [Abstract][Full Text] [Related]
13. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
[TBL] [Abstract][Full Text] [Related]
14. Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches.
Wilke C; Pujol-Calderón F; Barro C; Stransky E; Blennow K; Michalak Z; Deuschle C; Jeromin A; Zetterberg H; Schüle R; Höglund K; Kuhle J; Synofzik M
Clin Chem Lab Med; 2019 Sep; 57(10):1556-1564. PubMed ID: 31251725
[TBL] [Abstract][Full Text] [Related]
15. High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS.
Thebault S; R Tessier D; Lee H; Bowman M; Bar-Or A; Arnold DL; L Atkins H; Tabard-Cossa V; Freedman MS
Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):e598. PubMed ID: 31516913
[TBL] [Abstract][Full Text] [Related]
16. Quantitation of neurofilament light chain protein in serum and cerebrospinal fluid from patients with multiple sclerosis using the MSD R-PLEX NfL assay.
Ulndreaj A; Sohaei D; Thebault S; Pons-Belda OD; Fernandez-Uriarte A; Campbell C; Cheo D; Stengelin M; Sigal G; Freedman MS; Scarisbrick IA; Prassas I; Diamandis EP
Diagnosis (Berl); 2023 Aug; 10(3):275-280. PubMed ID: 36788117
[TBL] [Abstract][Full Text] [Related]
17. Retinal Nerve Fiber Layer Thickness Correlates with Serum and Cerebrospinal Fluid Neurofilament Levels and is Associated with Current Disability in Multiple Sclerosis.
Uzunköprü C; Yüceyar N; Yilmaz SG; Afrashi F; Ekmekçi Ö; Taşkiran D
Noro Psikiyatr Ars; 2021 Mar; 58(1):34-40. PubMed ID: 33795950
[TBL] [Abstract][Full Text] [Related]
18. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
19. A Comparison of Two Analytical Approaches for the Quantification of Neurofilament Light Chain, a Biomarker of Axonal Damage in Multiple Sclerosis.
Pafiti A; Krashias G; Tzartos J; Tzartos S; Stergiou C; Gaglia E; Smoleski I; Christodoulou C; Pantzaris M; Lambrianides A
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445963
[TBL] [Abstract][Full Text] [Related]
20. Serum neurofilament levels in patients with multiple sclerosis: A comparison of SIMOA and high sensitivity ELISA assays and contributing factors to ELISA levels.
Revendova KZ; Zeman D; Bunganic R; Karasova K; Volny O; Bar M; Kusnierova P
Mult Scler Relat Disord; 2022 Nov; 67():104177. PubMed ID: 36130459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
